Targeting SIRT1: A Potential Strategy for Combating Severe COVID‐19
BioMed Research International · 2025
DOI: 10.1155/bmri/9507417 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BioMed Research International, 2025. Verfasst von Hajar Shokri-Afra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gut and Liver Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran, mazums.ac.ir. Hauptthemen laut MEDLINE: COVID-19, Sirtuin 1, COVID-19 Drug Treatment. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sirtuin 1 (SIRT1) is a crucial regulator of cellular processes, including inflammation, metabolism, and stress responses, playing a significant role in the body′s defense mechanisms. During SARS‐CoV‐2 infection, SIRT1 plays a crucial role in modulating the immune response. This protein helps to enhance the antiviral response through deacetylating key transcription factors and regulating proinflammatory cytokines, thereby reducing the cytokine storm (an overwhelming immune response) associated with severe COVID‐19 cases. SIRT1 influences the expression of angiotensin‐converting enzyme 2 (ACE2), the primary receptor for SARS‐CoV‐2, thereby potentially mitigating viral entry and replication. Natural activators of SIRT1, such as resveratrol, have been shown to enhance its activity, offering promising avenues for therapeutic interventions aimed at bolstering the immune response during COVID‐19. Understanding the multifaceted role of SIRT1 in human defense mechanisms against SARS‐CoV‐2 could pave the way for innovative strategies to manage COVID‐19 and similar viral infections, emphasizing the importance of SIRT1 as a potential target for future therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gut and Liver Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran, mazums.ac.ir.
- Department of Biology, School of Sciences, University of Guilan, Rasht, Iran, guilan.ac.ir.
- Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran, mubabol.ac.ir.
- Department of Clinical Biochemistry and Laboratory Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran, tbzmed.ac.ir.
- Department of Clinical Biochemistry, School of Medicine, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran, thums.ac.ir.
- Health Sciences Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran, thums.ac.ir.
ORCID-Profile: Hajar Shokri-Afra, Fatemeh Saber Jeyvan, Zeinab Barartabar, Elham Yousefi Abdolmaleki, Davod Ilbeigi, Hadis Musavi, Yalda Malekzadegan
Zitieren
APA
Shokri-Afra, H., Saber Jeyvan, F., Barartabar, Z., Khanicheragh, P., Yousefi Abdolmaleki, E., Ilbeigi, D., Musavi, H., & Malekzadegan, Y. (2025). Targeting SIRT1: A Potential Strategy for Combating Severe COVID‐19. BioMed Research International. https://doi.org/10.1155/bmri/9507417
Vancouver
Shokri-Afra H, Saber Jeyvan F, Barartabar Z, Khanicheragh P, Yousefi Abdolmaleki E, Ilbeigi D, et al. Targeting SIRT1: A Potential Strategy for Combating Severe COVID‐19. BioMed Research International. 2025. doi:10.1155/bmri/9507417
BibTeX
@article{ShokriAfra2025,
author = {Shokri-Afra, Hajar and Saber Jeyvan, Fatemeh and Barartabar, Zeinab and Khanicheragh, Parisa and Yousefi Abdolmaleki, Elham and Ilbeigi, Davod and Musavi, Hadis and Malekzadegan, Yalda},
title = {Targeting SIRT1: A Potential Strategy for Combating Severe COVID‐19},
journal = {BioMed Research International},
year = {2025},
doi = {10.1155/bmri/9507417}
}
EUVIMED